The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...

"Overall, the comprehensive meta-analysis highlights that SGLT2 inhibitors are effective across a wide range of kidney ...

Experts say we’re in a golden age for treating chronic kidney disease, with new drugs like Ozempic yielding major results.

Balcinrenone is similar to finerenone (Kerendia), which is also a nonsteroidal MRA and was approved for the slowing of ...

Managing diabetes requires understanding how certain foods and drinks interact with medications. High-fat foods, added sugars ...

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...

A ketogenic diet may improve symptoms of depression, according to a new review and meta-analysis published in JAMA Psychiatry ...

To address knowledge gaps, investigators conducted a meta-analysis of more than 70,000 patients in 10 trials of SGLT2 inhibitors vs placebo to determine the relative risks of CKD progression across ...

Panelists discuss how payers typically require step therapy with SGLT2 inhibitors before approving nonsteroidal MRAs due to ...

A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.

Although SGLT2 inhibitors are standard-of-care treatments for CKD, type 2 diabetes, and heart failure (HF), the drugs are underutilized in clinical practice.